BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 26539832)

  • 21. Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer.
    Aure MR; Fleischer T; Bjørklund S; Ankill J; Castro-Mondragon JA; ; Børresen-Dale AL; Tost J; Sahlberg KK; Mathelier A; Tekpli X; Kristensen VN
    Genome Med; 2021 Apr; 13(1):72. PubMed ID: 33926515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1).
    Gu Y; Zhang Z; Yin J; Ye J; Song Y; Liu H; Xiong Y; Lu M; Zheng G; He Z
    J Exp Clin Cancer Res; 2017 Aug; 36(1):114. PubMed ID: 28859669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
    Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
    Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival differences of CIMP subtypes integrated with CNA information in human breast cancer.
    Wang H; Yan W; Zhang S; Gu Y; Wang Y; Wei Y; Liu H; Wang F; Wu Q; Zhang Y
    Oncotarget; 2017 Jul; 8(30):48807-48819. PubMed ID: 28415743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region.
    Al-Nakhle H; Smith L; Bell SM; Burns PA; Cummings M; Hanby AM; Lane S; Parker MD; Hughes TA; Speirs V
    Int J Oncol; 2013 Dec; 43(6):2039-45. PubMed ID: 24068253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles.
    Campoy EM; Branham MT; Mayorga LS; Roqué M
    BMC Cancer; 2019 Apr; 19(1):328. PubMed ID: 30953488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methylation-mediated repression of potential tumor suppressor miR-203a and miR-203b contributes to esophageal squamous cell carcinoma development.
    Liu Y; Dong Z; Liang J; Guo Y; Guo X; Shen S; Kuang G; Guo W
    Tumour Biol; 2016 Apr; 37(4):5621-32. PubMed ID: 26577858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma.
    Chen Y; Gao W; Luo J; Tian R; Sun H; Zou S
    Oncol Rep; 2011 Feb; 25(2):443-51. PubMed ID: 21165562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.
    Stefansson OA; Hermanowicz S; van der Horst J; Hilmarsdottir H; Staszczak Z; Jonasson JG; Tryggvadottir L; Gudjonsson T; Sigurdsson S
    BMC Cancer; 2017 Jul; 17(1):469. PubMed ID: 28679371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins.
    Myhre S; Lingjærde OC; Hennessy BT; Aure MR; Carey MS; Alsner J; Tramm T; Overgaard J; Mills GB; Børresen-Dale AL; Sørlie T
    Mol Oncol; 2013 Jun; 7(3):704-18. PubMed ID: 23562353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-29c plays a suppressive role in breast cancer by targeting the TIMP3/STAT1/FOXO1 pathway.
    Li W; Yi J; Zheng X; Liu S; Fu W; Ren L; Li L; Hoon DSB; Wang J; Du G
    Clin Epigenetics; 2018; 10():64. PubMed ID: 29796115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulforaphane epigenetically demethylates the CpG sites of the miR-9-3 promoter and reactivates miR-9-3 expression in human lung cancer A549 cells.
    Gao L; Cheng D; Yang J; Wu R; Li W; Kong AN
    J Nutr Biochem; 2018 Jun; 56():109-115. PubMed ID: 29525530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers.
    Ward AK; Mellor P; Smith SE; Kendall S; Just NA; Vizeacoumar FS; Sarker S; Phillips Z; Alvi R; Saxena A; Vizeacoumar FJ; Carlsen SA; Anderson DH
    Breast Cancer Res; 2016 Jan; 18(1):12. PubMed ID: 26810754
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
    Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
    Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic silencing of LPP/miR-28 in multiple myeloma.
    Li Z; Wong KY; Chan GC; Chim CS
    J Clin Pathol; 2018 Mar; 71(3):253-258. PubMed ID: 28775176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy.
    Zhang MY; Calin GA; Yuen KS; Jin DY; Chim CS
    Clin Epigenetics; 2020 Oct; 12(1):150. PubMed ID: 33076962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.
    Sizemore ST; Sizemore GM; Booth CN; Thompson CL; Silverman P; Bebek G; Abdul-Karim FW; Avril S; Keri RA
    Breast Cancer Res Treat; 2014 Jul; 146(1):25-40. PubMed ID: 24847890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells.
    Yu F; Jiao Y; Zhu Y; Wang Y; Zhu J; Cui X; Liu Y; He Y; Park EY; Zhang H; Lv X; Ma K; Su F; Park JH; Song E
    J Biol Chem; 2012 Jan; 287(1):465-473. PubMed ID: 22074923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes.
    Li Y; Li S; Chen J; Shao T; Jiang C; Wang Y; Chen H; Xu J; Li X
    Hum Mol Genet; 2014 Oct; 23(20):5378-93. PubMed ID: 24871326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epigenetic and genetic burden measures are associated with tumor characteristics in invasive breast carcinoma.
    O'Sullivan DE; Johnson KC; Skinner L; Koestler DC; Christensen BC
    Epigenetics; 2016 May; 11(5):344-53. PubMed ID: 27070496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.